Explore a selection of our essential drug information below, or:
Identification
- Summary
Calcifediol is an active metabolite of vitamin D used to treat hyperparathyroidism as well as to combat hypocalcemia in dialysis patients.
- Brand Names
- Rayaldee
- Generic Name
- Calcifediol
- DrugBank Accession Number
- DB00146
- Background
The major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties.
- Type
- Small Molecule
- Groups
- Approved, Nutraceutical
- Structure
Structure for Calcifediol (DB00146)
- Weight
- Average: 400.6371
Monoisotopic: 400.334130652 - Chemical Formula
- C27H44O2
- Synonyms
- (3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol
- (3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
- (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
- 25-hydroxycholecalciferol
- 25-Hydroxyvitamin D3
- Calcidiol
- Calcifediol
- Calcifédiol
- Calcifediol anhydrous
- Calcifediolum
Pharmacology
- Indication
Used to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Secondary hyperparathyroidism •••••••••••• ••••• ••••••• • •••••••••• ••• ••••• •• •• •••••• Treatment of Secondary hyperparathyroidism •••••••••••• ••••• ••••••• • •••••••••• ••• ••••• •• •• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Calcidiol is the precursor of vitamin D3. Vitamin D3 is a steroid hormone that has long been known for its important role in regulating body levels of calcium and phosphorus, in mineralization of bone, and for the assimilation of vitamin A. The classical manifestations of vitamin D deficiency is rickets, which is seen in children and results in bony deformaties including bowed long bones. Deficiency in adults leads to the disease osteomalacia. Both rickets and osteomalacia reflect impaired mineralization of newly synthesized bone matrix, and usually result from a combination of inadequate exposure to sunlight and decreased dietary intake of vitamin D. Common causes of vitamin D deficiency include genetic defects in the vitamin D receptor, severe liver or kidney disease, and insufficient exposure to sunlight. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma.
- Mechanism of action
Calcidiol is transformed in the kidney by 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to calcitriol, the active form of vitamin D3. Calcitriol binds to intracellular receptors that then function as transcription factors to modulate gene expression. Like the receptors for other steroid hormones and thyroid hormones, the vitamin D receptor has hormone-binding and DNA-binding domains. The vitamin D receptor forms a complex with another intracellular receptor, the retinoid-X receptor, and that heterodimer is what binds to DNA. In most cases studied, the effect is to activate transcription, but situations are also known in which vitamin D suppresses transcription. Calcitriol increases the serum calcium concentrations by: increasing GI absorption of phosphorus and calcium, increasing osteoclastic resorption, and increasing distal renal tubular reabsorption of calcium. Calcitriol appears to promote intestinal absorption of calcium through binding to the vitamin D receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein.
Target Actions Organism AVitamin D3 receptor agonistHumans - Absorption
Readily absorbed.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
Calcidiol undergoes hydroxylation in the mitochondria of kidney tissue, and this reaction is activated by the renal 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to produce calcitriol (1,25- dihydroxycholecalciferol), the active form of vitamin D3.
- Route of elimination
Not Available
- Half-life
288 hours
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Bone pain, constipation (especially in children or adolescents), diarrhea, drowsiness, dryness of mouth; headache (continuing), increased thirst, increase in frequency of urination, especially at night, or in amount of urine, irregular heartbeat, itching skin, loss of appetite, metallic taste, muscle pain, nausea or vomiting (especially in children or adolescents), unusual tiredness or weakness.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetyldigitoxin The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Calcifediol is combined with Acetyldigitoxin. Alfacalcidol The risk or severity of adverse effects can be increased when Calcifediol is combined with Alfacalcidol. Aluminum hydroxide The serum concentration of Aluminum hydroxide can be increased when it is combined with Calcifediol. Beclomethasone dipropionate The therapeutic efficacy of Calcifediol can be decreased when used in combination with Beclomethasone dipropionate. Bendroflumethiazide The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Calcifediol. - Food Interactions
- Take with or without food. A high-fat, high-calorie meal may increase the AUC and Cmax of calcifediol by up to 3.5 and 5 fold, respectively.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Calcifediol hydrate P6YZ13C99Q 63283-36-3 WRLFSJXJGJBFJQ-WPUCQFJDSA-N - International/Other Brands
- Calderol (Upjohn) / Caldiol (Medica) / De Kai (China Otsuka) / Dedrogyl (Desma) / Dédrogyl (DB) / Didrogyl (Bruno Farm.) / Hidroferol (Faes)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Rayaldee Capsule 30 mcg Oral EIRGEN PHARMA LIMITED Not applicable Not applicable Canada 
Rayaldee Capsule, extended release 30 ug/1 Oral Opko Pharmaceuticals Llc 2016-10-25 Not applicable US 
Rayaldee Capsule, extended release 30 ug/1 Oral Opko Pharmaceuticals Llc 2024-03-11 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image HEPASELAMİN AMİNOASİT IV İNFÜZYON ÇÖZELTİSİ 500 ML SETLİ ŞİŞE Calcifediol (0.9 %) + Ademetionine (0.24 %) + Adenine (0.8 %) + Ascorbic acid (0.6 %) + Aspartame (0.9 %) + Biotin (0.1 %) + Cysteine (0.066 %) + Lysine (0.61 %) + Methionine (0.5 %) + NADH (0.45 %) + Phosphoric acid (0.115 %) + Thiamine (0.02 %) + Tryptophan (1.1 %) + Tyrosine (0.1 %) + Valine (0.77 %) + Vitamin A (0.84 %) Solution Intravenous OSEL İLAÇ SAN. VE TİC. A.Ş. 2003-12-31 Not applicable Turkey 
HEPASELAMİN AMİNOASİT IV İNFÜZYON ÇÖZELTİSİ 500 ML SETSİZ ŞİŞE Calcifediol (0.9 %) + Ademetionine (0.24 %) + Adenine (0.8 %) + Ascorbic acid (0.6 %) + Aspartame (0.9 %) + Biotin (0.1 %) + Cysteine (0.066 %) + Lysine (0.61 %) + Methionine (0.5 %) + NADH (0.45 %) + Phosphoric acid (0.115 %) + Thiamine (0.02 %) + Tryptophan (1.1 %) + Tyrosine (0.1 %) + Valine (0.77 %) + Vitamin A (0.84 %) Solution Intravenous OSEL İLAÇ SAN. VE TİC. A.Ş. 2003-12-31 Not applicable Turkey HEPATAMINE %8 500 ML(SETLI) Calcifediol (0.9 %) + Ademetionine (0.24 %) + Adenine (0.8 %) + Ascorbic acid (0.6 %) + Aspartame (0.9 %) + Biotin (0.1 %) + Cysteine (0.066 %) + Lysine (0.61 %) + Methionine (0.5 %) + NADH (0.45 %) + Phosphoric acid (0.115 %) + Sodium bisulfite (0.01 %) + Thiamine (0.02 %) + Tryptophan (1.1 %) + Tyrosine (0.1 %) + Valine (0.77 %) + Vitamin A (0.84 %) Solution Intravenous ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş. 1990-01-16 2024-01-23 Turkey HEPATAMINE %8 500 ML(SETSIZ) Calcifediol (0.9 %) + Ademetionine (0.24 %) + Adenine (0.8 %) + Ascorbic acid (0.6 %) + Aspartame (0.9 %) + Biotin (0.1 %) + Cysteine (0.066 %) + Lysine (0.61 %) + Methionine (0.5 %) + NADH (0.45 %) + Phosphoric acid (0.115 %) + Sodium bisulfite (0.01 %) + Thiamine (0.02 %) + Tryptophan (1.1 %) + Tyrosine (0.1 %) + Valine (0.77 %) + Vitamin A (0.84 %) Solution Intravenous ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş. 1990-01-16 2024-01-23 Turkey
Categories
- ATC Codes
- A11CC06 — Calcifediol
- A11CC — Vitamin D and analogues
- A11C — VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO
- A11 — VITAMINS
- A — ALIMENTARY TRACT AND METABOLISM
- Drug Categories
- Alimentary Tract and Metabolism
- Anti-Parathyroid Agents
- Bone Density Conservation Agents
- Calcium Homeostasis
- Cholestanes
- Cholestenes
- Diet, Food, and Nutrition
- Food
- Fused-Ring Compounds
- Lipids
- Membrane Lipids
- Micronutrients
- Physiological Phenomena
- Secosteroids
- Steroids
- Sterols
- Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins
- Vitamin D and Analogues
- Vitamins
- Vitamins (Fat Soluble)
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Vitamin D and derivatives
- Direct Parent
- Vitamin D and derivatives
- Alternative Parents
- Triterpenoids / Tertiary alcohols / Secondary alcohols / Cyclic alcohols and derivatives / Hydrocarbon derivatives
- Substituents
- Alcohol / Aliphatic homopolycyclic compound / Cyclic alcohol / Hydrocarbon derivative / Organic oxygen compound / Organooxygen compound / Secondary alcohol / Tertiary alcohol / Triterpenoid
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- diol, D3 vitamins, hydroxycalciol (CHEBI:17933) / Vitamin D3 and derivatives (C01561) / Vitamin D3 and derivatives (LMST03020246)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- T0WXW8F54E
- CAS number
- 19356-17-3
- InChI Key
- JWUBBDSIWDLEOM-DTOXIADCSA-N
- InChI
- InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1
- IUPAC Name
- (1S,3Z)-3-{2-[(1R,3aS,4E,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexan-1-ol
- SMILES
- C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
References
- Synthesis Reference
Dae-Jung Kang, Jong-Hyuk Im, Hyun-Jung Jung, Jae-Hoon Kang, "BUFFER COMPOSITION FOR CATALYZING THE PREPARATION OF CALCITRIOL OR CALCIFEDIOL AND METHOD FOR PREPARING CALCITRIOL OR CALCIFEDIOL USING SAME." U.S. Patent US20120064584, issued March 15, 2012.
US20120064584- General References
- FDA Approved Drug Products: RAYALDEE (calcifediol) extended-release capsules [Link]
- External Links
- Human Metabolome Database
- HMDB0003550
- KEGG Compound
- C01561
- PubChem Compound
- 5283731
- PubChem Substance
- 46505690
- ChemSpider
- 4446820
- BindingDB
- 50521013
- 1855064
- ChEBI
- 17933
- ChEMBL
- CHEMBL1040
- ZINC
- ZINC000004474414
- Therapeutic Targets Database
- DAP000290
- PharmGKB
- PA164745614
- PDBe Ligand
- VDY
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Calcifediol
- PDB Entries
- 1j78 / 1mz9 / 3a51 / 5ien / 5ieo / 5iep
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Not Available Coronavirus Disease 2019 (COVID‑19) 1 somestatus stop reason just information to hide Not Available Recruiting Not Available Coronavirus Disease 2019 (COVID‑19) / COVID-19 Pneumonia 1 somestatus stop reason just information to hide 4 Completed Treatment Bronchial Asthma 1 somestatus stop reason just information to hide 4 Completed Treatment Cardiovascular Disease (CVD) / Rickets 1 somestatus stop reason just information to hide 4 Completed Treatment CKD Stage 3 / Secondary Hyperparathyroidism Due to Renal Causes / Stage 4 Chronic Kidney Disease / Vitamin D Insufficiency 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Organon usa inc
- Packagers
- Organon Pharmaceuticals
- Dosage Forms
Form Route Strength Solution / drops Oral 0.15 MG/ML Solution Intravenous Capsule Oral 266 Mikrogramm Capsule, liquid filled Oral 0.266 mg Solution / drops Oral 0266 MG/0.5ML Capsule Oral 0.266 MG Capsule Oral Capsule Oral 30 MICROGRAMMI Capsule Oral 30 mcg Capsule, extended release Oral 30 ug/1 - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US8906410 No 2014-12-09 2027-02-02 US US6582727 No 2003-06-24 2020-08-22 US US8361488 No 2013-01-29 2028-07-19 US US9408858 No 2016-08-09 2028-04-25 US US9498486 No 2016-11-22 2028-04-25 US US8778373 No 2014-07-15 2028-04-25 US US8426391 No 2013-04-23 2028-08-27 US US8207149 No 2012-06-26 2028-04-25 US US9861644 No 2018-01-09 2034-03-14 US US9943530 No 2018-04-17 2027-02-02 US US9925147 No 2018-03-27 2028-04-25 US US10213442 No 2019-02-26 2027-02-02 US US10300078 No 2019-05-28 2034-03-14 US US10357502 No 2019-07-23 2034-03-14 US US11154509 No 2021-10-26 2028-04-25 US US11253528 No 2014-03-14 2034-03-14 US US11801253 No 2010-09-07 2030-09-07 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility Insoluble Not Available logP 6 Not Available - Predicted Properties
Property Value Source Water Solubility 0.0022 mg/mL ALOGPS logP 6.71 ALOGPS logP 5.65 Chemaxon logS -5.3 ALOGPS pKa (Strongest Acidic) 18.38 Chemaxon pKa (Strongest Basic) -0.98 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 40.46 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 125.06 m3·mol-1 Chemaxon Polarizability 50.38 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9953 Blood Brain Barrier + 0.9164 Caco-2 permeable + 0.8891 P-glycoprotein substrate Substrate 0.7454 P-glycoprotein inhibitor I Inhibitor 0.5209 P-glycoprotein inhibitor II Inhibitor 0.6087 Renal organic cation transporter Non-inhibitor 0.7849 CYP450 2C9 substrate Non-substrate 0.8379 CYP450 2D6 substrate Non-substrate 0.9004 CYP450 3A4 substrate Substrate 0.7815 CYP450 1A2 substrate Non-inhibitor 0.8874 CYP450 2C9 inhibitor Non-inhibitor 0.9229 CYP450 2D6 inhibitor Non-inhibitor 0.9488 CYP450 2C19 inhibitor Non-inhibitor 0.7885 CYP450 3A4 inhibitor Non-inhibitor 0.7968 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.56 Ames test Non AMES toxic 0.8612 Carcinogenicity Non-carcinogens 0.917 Biodegradation Not ready biodegradable 0.991 Rat acute toxicity 4.1429 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8189 hERG inhibition (predictor II) Non-inhibitor 0.7589
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 217.3865044 predictedDarkChem Lite v0.1.0 [M-H]- 194.9139647 predictedDarkChem Standard v0.1.0 [M-H]- 207.6283044 predictedDarkChem Lite v0.1.0 [M-H]- 218.6883044 predictedDarkChem Lite v0.1.0 [M-H]- 202.94073 predictedDeepCCS 1.0 (2019) [M+H]+ 216.4439044 predictedDarkChem Lite v0.1.0 [M+H]+ 202.7943044 predictedDarkChem Lite v0.1.0 [M+H]+ 206.0010044 predictedDarkChem Lite v0.1.0 [M+H]+ 218.5856044 predictedDarkChem Lite v0.1.0 [M+H]+ 204.76723 predictedDeepCCS 1.0 (2019) [M+Na]+ 216.1276044 predictedDarkChem Lite v0.1.0 [M+Na]+ 203.3194044 predictedDarkChem Lite v0.1.0 [M+Na]+ 206.0874044 predictedDarkChem Lite v0.1.0 [M+Na]+ 217.2326044 predictedDarkChem Lite v0.1.0 [M+Na]+ 210.37303 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Nuclear receptor for calcitriol, the active form of vitamin D3 which mediates the action of this vitamin on cells (PubMed:10678179, PubMed:15728261, PubMed:16913708, PubMed:28698609, PubMed:37478846). Enters the nucleus upon vitamin D3 binding where it forms heterodimers with the retinoid X receptor/RXR (PubMed:28698609). The VDR-RXR heterodimers bind to specific response elements on DNA and activate the transcription of vitamin D3-responsive target genes (PubMed:28698609). Plays a central role in calcium homeostasis (By similarity). Also functions as a receptor for the secondary bile acid lithocholic acid (LCA) and its metabolites (PubMed:12016314, PubMed:32354638)
- Specific Function
- bile acid nuclear receptor activity
- Gene Name
- VDR
- Uniprot ID
- P11473
- Uniprot Name
- Vitamin D3 receptor
- Molecular Weight
- 48288.64 Da
References
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- A cytochrome P450 monooxygenase involved in vitamin D metabolism and in calcium and phosphorus homeostasis. Catalyzes the rate-limiting step in the activation of vitamin D in the kidney, namely the hydroxylation of 25-hydroxyvitamin D3/calcidiol at the C1alpha-position to form the hormonally active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3/calcitriol that acts via the vitamin D receptor (VDR) (PubMed:10518789, PubMed:10566658, PubMed:12050193, PubMed:22862690, PubMed:9486994). Has 1alpha-hydroxylase activity on vitamin D intermediates of the CYP24A1-mediated inactivation pathway (PubMed:10518789, PubMed:22862690). Converts 24R,25-dihydroxyvitamin D3/secalciferol to 1-alpha,24,25-trihydroxyvitamin D3, an active ligand of VDR. Also active on 25-hydroxyvitamin D2 (PubMed:10518789). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via FDXR/adrenodoxin reductase and FDX1/adrenodoxin (PubMed:22862690)
- Specific Function
- calcidiol 1-monooxygenase activity
- Gene Name
- CYP27B1
- Uniprot ID
- O15528
- Uniprot Name
- 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial
- Molecular Weight
- 56503.475 Da
References
- Schuster I: Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta. 2011 Jan;1814(1):186-99. doi: 10.1016/j.bbapap.2010.06.022. Epub 2010 Jul 7. [Article]
- Bernad M, Jaramillo G, Aguado P, del Campo T, Coya J, Martin Mola E, Gijon Banos J, Saldana Barrera H, Martinez ME: [Polymorphism of the gene of vitamin D receptor and bone mineral density in postmenopausal women]. Med Clin (Barc). 1999 May 15;112(17):651-5. [Article]
- Diesel B, Radermacher J, Bureik M, Bernhardt R, Seifert M, Reichrath J, Fischer U, Meese E: Vitamin D(3) metabolism in human glioblastoma multiforme: functionality of CYP27B1 splice variants, metabolism of calcidiol, and effect of calcitriol. Clin Cancer Res. 2005 Aug 1;11(15):5370-80. [Article]
- Eto TA, Nakamura Y, Taniguchi T, Miyamoto K, Nagatomo J, Maeda Y, Higashi S, Okuda K, Setoguchi T: Assay of 25-hydroxyvitamin D3 1 alpha-hydroxylase in rat kidney mitochondria. Anal Biochem. 1998 Apr 10;258(1):53-8. [Article]
- Hart GR, Furniss JL, Laurie D, Durham SK: Measurement of vitamin D status: background, clinical use, and methodologies. Clin Lab. 2006;52(7-8):335-43. [Article]
- Vigo Gago E, Cadarso-Suarez C, Perez-Fernandez R, Romero Burgos R, Devesa Mugica J, Segura Iglesias C: Association between vitamin D receptor FokI. Polymorphism and serum parathyroid hormone level in patients with chronic renal failure. J Endocrinol Invest. 2005 Feb;28(2):117-21. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- A cytochrome P450 monooxygenase with a key role in vitamin D catabolism and calcium homeostasis. Via C24- and C23-oxidation pathways, catalyzes the inactivation of both the vitamin D precursor calcidiol (25-hydroxyvitamin D(3)) and the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)) (PubMed:11012668, PubMed:15574355, PubMed:16617161, PubMed:24893882, PubMed:29461981, PubMed:8679605). With initial hydroxylation at C-24 (via C24-oxidation pathway), performs a sequential 6-step oxidation of calcitriol leading to the formation of the biliary metabolite calcitroic acid (PubMed:15574355, PubMed:24893882). With initial hydroxylation at C-23 (via C23-oxidation pathway), catalyzes sequential oxidation of calcidiol leading to the formation of 25(OH)D3-26,23-lactone as end product (PubMed:11012668, PubMed:8679605). Preferentially hydroxylates at C-25 other vitamin D active metabolites, such as CYP11A1-derived secosteroids 20S-hydroxycholecalciferol and 20S,23-dihydroxycholecalciferol (PubMed:25727742). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via FDXR/adrenodoxin reductase and FDX1/adrenodoxin (PubMed:8679605)
- Specific Function
- 1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity
- Gene Name
- CYP24A1
- Uniprot ID
- Q07973
- Uniprot Name
- 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial
- Molecular Weight
- 58874.695 Da
References
- Wjst M, Altmuller J, Faus-Kessler T, Braig C, Bahnweg M, Andre E: Asthma families show transmission disequilibrium of gene variants in the vitamin D metabolism and signalling pathway. Respir Res. 2006 Apr 6;7:60. doi: 10.1186/1465-9921-7-60. [Article]
- CYP24A1 gene - Genetics Home Reference - NIH [Link]
Drug created at June 13, 2005 13:24 / Updated at August 02, 2024 07:22